Abstract
Teva Pharmaceutical Industries continues to divest products to satisfy antitrust regulators assessing its planned acquisition of Allergan’s generic drug business. Impax Laboratories will pay $586 million for 15 marketed generics plus the rights to products not yet launched and to the pending Abbreviated New Drug Application (ANDA) for the generic equivalent of Concerta, a product on which the two companies collaborated. Sagent Pharmaceuticals, meanwhile, will pay $40 million for five ANDAs pending in the U.S. Earlier this month, Teva sold a raft of ANDAs to Dr. Reddy’s Laboratories.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
